Dr. Mohamed Adam 

Surgical Oncology, Director of Peritoneal Surface Malignancies
University of California, San Francisco
California
View Contact Information

Schedule a Conversation with a HIPEC Surgeon

The surgeon or staff member will make their best effort to call you at your requested time. If they become unavailable you will receive a text.

Fill out my online form.

Board Certified

Board certification by an ABMS Member Board is the premier, independently assessed credential attainable in medicine today.

Dr. Mohamed Adam is affiliated with University of California, San Francisco

Fellowship Experience

University of Pittsburgh Medical Center

Additional Information

Dr. Mohamed Abdelgadir Adam is an Assistant Professor in the Division of Surgical Oncology, specializing in advanced gastrointestinal tumors with a particular emphasis on cancers affecting the peritoneal surface, liver, pancreas, and bile ducts. He serves as the Director of Peritoneal Surface Malignancies at UCSF, overseeing the implementation of regional treatment strategies for metastatic cancers, including cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Dr. Adam also has extensive expertise in robotic minimally invasive pancreato-biliary surgery, notably performing robotic pancreaticoduodenectomy (Whipple procedure).

Dr. Adam earned his medical degree from the Faculty of Medicine and Health Sciences and completed his general surgery training at Duke University Medical Center. He furthered his education with a two-year fellowship in complex surgical oncology at the University of Pittsburgh Medical Center, complemented by research fellowships at Duke University. Currently, Dr. Adam has authored over 150 publications and leads a prominent research group dedicated to peritoneal surface tumors, known for its significant contributions to the field through extensive publications and impactful research projects. He plays an active role in national guidelines, serving as a member of the NCCN guidelines for appendiceal cancer and the Peritoneal Surface Malignancies Group.